Published in Rheumatology (Oxford) on August 12, 2014
Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol (2016) 0.83
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol (2016) 0.80
Defective structural RNA processing in relapsing-remitting multiple sclerosis. Genome Biol (2015) 0.78
Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression. Nat Commun (2017) 0.77
Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver. J Immunol Res (2016) 0.75
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
Nitric oxide and the immune response. Nat Immunol (2001) 10.00
NF-kappaB: a key role in inflammatory diseases. J Clin Invest (2001) 9.66
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev (2010) 4.48
Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 3.53
Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A (1997) 2.80
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest (1993) 2.66
Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes (2001) 2.61
Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (2005) 2.47
Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev (2005) 2.42
The pharmacology and clinical use of methotrexate. N Engl J Med (1983) 2.29
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
Methotrexate--how does it really work? Nat Rev Rheumatol (2010) 2.24
NF-kappaB in inflammatory bowel disease. J Intern Med (2008) 2.21
Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity. J Mol Cell Cardiol (2009) 2.09
p53 is a suppressor of inflammatory response in mice. FASEB J (2005) 1.91
Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1985) 1.88
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum (1996) 1.79
Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum (1995) 1.78
p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J (2010) 1.77
Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways. J Biol Chem (2009) 1.72
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) (2008) 1.59
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum (2003) 1.41
Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis (2007) 1.39
Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes. J Immunol (2005) 1.24
Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol (2001) 1.24
Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. J Biol Chem (2009) 1.20
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis (2000) 1.16
Tumor suppressor protein (p)53, is a regulator of NF-kappaB repression by the glucocorticoid receptor. Proc Natl Acad Sci U S A (2011) 1.14
Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene (2000) 1.10
NF-kappaB: Holy Grail for rheumatoid arthritis? Arthritis Rheum (2004) 1.05
Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum (2011) 0.99
Molecular mechanism of methotrexate action in inflammation. Inflammation (1992) 0.93
p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. Ann Rheum Dis (2003) 0.93
Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum (2011) 0.92
Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol (2012) 0.90
Role of increased guanosine triphosphate cyclohydrolase-1 expression and tetrahydrobiopterin levels upon T cell activation. J Biol Chem (2011) 0.88
Human dihydrofolate reductase: reduction of alternative substrates, pH effects, and inhibition by deazafolates. Biochemistry (1992) 0.84
The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis. Clin Exp Rheumatol (2011) 0.83
Glucocorticoid receptor, nuclear factor kappaB, activator protein-1 and C-jun N-terminal kinase in systemic lupus erythematosus patients. Neuroimmunomodulation (2007) 0.81